Status:
COMPLETED
Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsors:
First Affiliated Hospital of Fujian Medical University
Nanchang University
Conditions:
Immunosuppression
Hepatocellular Carcinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.
Eligibility Criteria
Inclusion
- All liver transplantation patients with hepatocellular carcinoma in our center between Jan 2005 and Dec 2009 were potentially eligible for enrollment
Exclusion
- the recipient pass away within 3 month following up liver transplantation
- Inability to provide written informed consent prior to study entry
- acute rejection are treated only with steroids
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01137084
Start Date
January 1 2005
End Date
December 1 2009
Last Update
June 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China, 200080